Sangamo Therapeutics (SGMO) Net Margin (2016 - 2025)
Sangamo Therapeutics has reported Net Margin over the past 16 years, most recently at 263.0% for Q4 2025.
- Quarterly results put Net Margin at 263.0% for Q4 2025, up 9694.0% from a year ago — trailing twelve months through Dec 2025 was 310.81% (down 13596.0% YoY), and the annual figure for FY2025 was 310.81%, down 14136.0%.
- Net Margin for Q4 2025 was 263.0% at Sangamo Therapeutics, up from 6012.05% in the prior quarter.
- Over the last five years, Net Margin for SGMO hit a ceiling of 18.99% in Q3 2024 and a floor of 10205.61% in Q1 2024.
- Median Net Margin over the past 5 years was 200.89% (2022), compared with a mean of 1814.9%.
- Biggest five-year swings in Net Margin: crashed -1021899bps in 2024 and later soared 1003914bps in 2025.
- Sangamo Therapeutics' Net Margin stood at 166.96% in 2021, then dropped by -14bps to 190.87% in 2022, then plummeted by -1447bps to 2952.74% in 2023, then surged by 88bps to 359.94% in 2024, then increased by 27bps to 263.0% in 2025.
- The last three reported values for Net Margin were 263.0% (Q4 2025), 6012.05% (Q3 2025), and 109.18% (Q2 2025) per Business Quant data.